BridGene Biosciences Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $28M

  • Investors
  • 13

BridGene Biosciences General Information

Description

Operator of a biotechnology company intended to develop drugs for traditionally untreatable targets. The company combines technologies, including covalent chemistry, chemical proteomics, and quantitative mass spectrometry, to develop therapeutics and covalent small-molecule inhibitors, enabling healthcare industries to find new drug targets and develop new drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 75 Nicholson Lane
  • San Jose, CA 95134
  • United States
+1 (408)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 75 Nicholson Lane
  • San Jose, CA 95134
  • United States
+1 (408)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BridGene Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B1) 16-Oct-2025 $28M Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 27-Jul-2022 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 05-May-2021 Completed Clinical Trials - Phase 1
2. Grant 18-Sep-2020 $299K Completed Startup
1. Grant 01-Jan-2018 $223K Completed Startup
To view BridGene Biosciences’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

BridGene Biosciences Patents

BridGene Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024434673-A1 Preparation of compound and crystalline forms thereof Pending 20-Mar-2024
WO-2025198588-A1 Preparation of compound and crystalline forms thereof Pending 20-Mar-2024
AU-2023341864-A1 Yap/taz-tead oncoproteins inhibitors Pending 15-Sep-2022
EP-4587424-A1 Yap/taz-tead oncoproteins inhibitors Pending 15-Sep-2022
US-20260347319-A1 Yap/taz-tead oncoproteins inhibitors Pending 15-Sep-2022 C07D205/04
To view BridGene Biosciences’s complete patent history, request access »

BridGene Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BridGene Biosciences Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bayland Capital Corporate Venture Capital Minority
Gaorong Ventures Venture Capital Minority
Grains Valley Venture Capital Venture Capital Minority
Proxima Capital Venture Capital Minority
Proxima Investments Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

BridGene Biosciences FAQs

  • When was BridGene Biosciences founded?

    BridGene Biosciences was founded in 2018.

  • Where is BridGene Biosciences headquartered?

    BridGene Biosciences is headquartered in San Jose, CA.

  • What is the size of BridGene Biosciences?

    BridGene Biosciences has 31 total employees.

  • What industry is BridGene Biosciences in?

    BridGene Biosciences’s primary industry is Drug Discovery.

  • Is BridGene Biosciences a private or public company?

    BridGene Biosciences is a Private company.

  • What is BridGene Biosciences’s current revenue?

    The current revenue for BridGene Biosciences is .

  • How much funding has BridGene Biosciences raised over time?

    BridGene Biosciences has raised $78.5M.

  • Who are BridGene Biosciences’s investors?

    Bayland Capital, Gaorong Ventures, Grains Valley Venture Capital, Proxima Capital, and Proxima Investments are 5 of 13 investors who have invested in BridGene Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process